Table 3.
Effects of Lactobacillus on the experimental AD.
| Probiotic | strain | Experimental animal | Interventions | Outcome | Reference |
|---|---|---|---|---|---|
| L. rhamnosus | RHT3201 | six-week-old female NC/Nga mice | 1×108, 1×109, or 1×1010 cells/d, for 8 weeks. | improved dermatitis scores and frequency of scratching | (Lee et al., 2016) |
| LGG | two litters of Beagles (same sire and dam) with AD | 200 × 109 CFU/d, ten Culturelle® capsule; offspring from the second pregnancy, LGG, 100 × 109 CFU/d |
decreased allergen-specific IgE and partially prevented AD | (Marsella et al., 2012) | |
| 2 adult beagles with severe AD and 16 pups | One capsule containing a minimum of LGG 20×109 CFUs; first litter female dogs did not receive LGG. During the second pregnancy, a dosage of 10 capsules/d LGG from week 3 of gestation and continued throughout lactation. During the third pregnancy, 5 capsules/d from 3 weeks to 6 months of age |
decreased serum titer of allergen-specific IgE and moderated reaction to intradermal testing | (Marsella, 2009) | ||
| specific pathogen-free NC/Nga mice | 30–50 mg/d | increased plasma IL-10 levels and enhanced IL-10 mRNA expression in both Peyer’s patches and mesenteric lymph nodes | (Sawada et al., 2007) | ||
| CGMCC 1.3724 (LPR) | specific-pathogen free pregnant NC / NgaTnd mice, pups until 12 weeks of age | 5 ×108 CFU/ ml | decreased clinical symptoms of dermatitis, reduced scratching frequency | (Tanaka et al., 2009) | |
| L. acidophilus | L-92 | ICR mice BALB/c mice BALB/c and NC/Nga mice |
3 and 30 mg/kg | inhibited vascular permeability in both passive cutaneous anaphylaxis | (Shah et al., 2010) |
| L-55 | female NC/Nga mice (5 weeks old) with AD-like skin lesions | 1 and 10 mg/d, for 75 days | inhibited dermatitis score, ear swelling, scratching behavior | (Sunada et al., 2008) | |
| L. plantarum | MG4221 | NC/Nga mice (male, 4 weeks old) | a single dose (7 μg·cm−2) of 200 μL of PM2.5 (500 μg·mL−1) with 2% dinitrochlorobenzene another single dose (7 μg·cm−2) of 200 μL of PM2.5 (500 μg·mL−1) with 0.2% dinitrochlorobenzene |
decreased transepidermal water loss and erythema; decreased scratching behavior | (Hong et al., 2021a) |
| LM1004 | AD-induced rat (histamine-induced vasodilation) and mouse (pruritus and contact dermatitis) | 2 × 1012 cells, for 28 days | reduced vasodilation, pruritus, edema, and serum histamine | (Kim et al., 2019a) | |
| NCIMB8826 | APOC1+/+ mice | 3×108 CFU, three times a week, for 8 weeks | ameliorated skin pathology, improved skin barrier integrity, eliminated of skin thickening, and fewer excoriations | (Mariman et al., 2016) | |
| L. sakei | ProBio65 | dogs with CAD | 2 × 109 CFU/g, for 2 months | reduced disease severity index, CASESI score values | (Kim et al., 2015a) |
| 25 male 6-week-old NC/Nga mice | 5×109 CFU/ml, 200 μL/d, for 2 weeks | improved condition of skin and reduced scratching frequency | (Kim et al., 2013) | ||
| mice triggered by allergen | 1 ×108 CFU/mL, 200 μL/d, for 2 weeks | faster recovery of AD | (Park et al., 2008) | ||
| WIKIM30 | wild-type male BALB/c mice | 2 × 109 CFU bacteria, 200 μL/d | reduced AD-like skin lesions | (Kwon et al., 2018) | |
| L. reuteri | Fn041 | seven-week-old male and female BALB/C mice | 1×109 CFU/d, once a day, 100 μL each time, each time | suppressed AD symptoms such as skin swelling, mast cell and eosinophil infiltration | (Zhao et al., 2022) |
| Japan Collection of Microorganisms 1112 | specific pathogen-free male NC/Nga mice (aged 10 weeks) | 0.1% (w/v) Lactobacillus water extract (LW)-treated, and 1.0% (w/v) LW-treated; 0.1% LW in 80% ethanol, or 1.0% LW in 80% ethanol, twice weekly for one week |
suppressed the development of house dust mite-induced atopic skin lesions and thymus and activation-regulated chemokine expression | (Kawahara et al., 2018) | |
| L. paracasei | KBL382 | mice with Dermatophagoides farinae extract -induced AD | 1 × 109 CFU/d, for 4 weeks | reduced AD-associated skin lesions and epidermal thickening | (Kim et al., 2020a) |
| K71 | 41 dogs with mild to moderate cAD | 5 mg/kg, once daily, for 12 weeks | decreased CADESI, and pruritus scores; the reduced medication scores | (Ohshima-Terada et al., 2015) | |
| WK3001 | five-week-old male NC/Nga mice | basic diet at concentrations of 0.03% (low dose) or 0.3% (high dose) | reduced development of AD-like skin lesions | (Wakabayashi et al., 2008) | |
| L. casei | KCTC 12398BP | male NC/Nga mice | 1, 10, and 100 μg/mL of P14 0.1, 0.2, 1, 5, and 10 μg/mL of P14 |
downregulated AD index and scratching score in AD-like NC/Nga mice | (Kim et al., 2015b) |
| JCM 1134T | six-week-old male NC/Nga mice | NC/Nga mice were divided into four groups of six each and administered CD, DD (500 mg of dextran per day) LD (1×107 CFU of lyophilized L. casei subsp. casei per day) LDD (1×107 CFU of lyophilized L. casei subsp. casei and 500 mg of dextran per day) (control diet; CD) (dextran diet; DD) (L. casei subsp. casei diet; LD) (L. casei subsp. casei and dextran diet; LDD) |
decreased clinical skin severity scores and total IgE levels | (Ogawa et al., 2006) | |
| L. delbrueckii | OLL1073R-1 | specific-pathogen-free female NC/Nga mice and BALB/c mice, (4- or 5-wk-old). | bacterial, 1 mg/d | inhibited development of dermatitis and elevation of an acute inflammation marker, serum amyloid A | (Kano et al., 2013) |
| R-037 | female BALB/c mice (5-weeks-old) and male NC/Nga mice (7-weeks-old) | 5 g/d/mouse, from day 0 to day 55 | reduced inflammatory auricular thickness and alleviated the AD clinical score | (Watanabe et al., 2009) | |
| L. johnsonii | NCC533 | NC/NgaTnd mice | 4 weeks | suppressed exacerbation of the clinical severity of dermatitis and suppressed epidermal hyperplasia and infiltration of inflammatory cells in skin | (Tanaka et al., 2008) |
| pups of 4 pregnant NC/Nga mice. | 1010 cells, from 20 to 22 days of age via oral administration | enhanced gene expression of the proinflammatory cytokines [interleukin-8 (IL-8), IL-12 and IL-23] and decreased gene expression of CD86 | (Inoue et al., 2007) | ||
| L. brevis | NS1401 | female NC/Nga mice (24 Six-weeks old) | 5 × 108 CFU/d per mouse, for 8 weeks | reduced skin thickness and infiltration of mast cells and eosinophils in skin lesions and the size and number of immune cells in draining lymph nodes | (Choi et al., 2017) |
| SBC8803 | male 5-week-old NC/Nga mice | 0%, 0.05% or 0.5%, once a week for 9 weeks. | inhibited ear swelling, and suppressed the development of dermatitis. | (Segawa et al., 2008a) |